Divi's Laboratories today said its unit at Choutuppal in Telangana has undergone successful inspection by the US health regulator with no observations.
The company's unit-I at Choutuppal has had an inspection by the United States Food and Drug Administration (USFDA) from May 14-16, 2018, Divi's Labs said in a filing to BSE.
"This was a general cGMP inspection by USFDA. The inspection has been concluded with no 483 observations," it added.
As per USFDA, form 483 observations are issued after conclusion of inspection to notify the company's management of objectionable conditions at its facility.
Shares of Divi's Laboratories today closed at Rs 1,166.15 per scrip on BSE, up 1.50 per cent from the previous close.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app